This inventor holds 6 USPTO granted patents and 2 published patent applications, plus 1 CIPO patent and 1 EPO patent. Top assignee: 4D Pharma Research Limited. Active years: 2017-2022.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2017-2022
Title: Innovations by Domenico Panzica
Introduction
Domenico Panzica is a notable inventor based in Aberdeen, GB. He has made significant contributions to the field of biotechnology, particularly in the development of compositions that utilize bacterial strains for various medical applications. With a total of six patents to his name, Panzica's work is paving the way for advancements in immune system stimulation and cancer treatment.
Latest Patents
Among his latest patents, Panzica has developed compositions comprising bacterial strains aimed at stimulating the immune system and preventing diseases. Additionally, he has created compositions that focus on treating and preventing cancer, showcasing his commitment to addressing critical health challenges through innovative solutions.
Career Highlights
Domenico Panzica is currently associated with 4D Pharma Research Limited, where he continues to push the boundaries of research in microbiome therapeutics. His work at this company highlights his dedication to harnessing the power of bacteria in medicine.
Collaborations
Panzica collaborates with talented individuals such as Imke Elisabeth Mulder and Amy Beth Holt, contributing to a dynamic research environment that fosters innovation and discovery.
Conclusion
Domenico Panzica's contributions to the field of biotechnology through his patents and research at 4D Pharma Research Limited exemplify the impact of innovative thinking in addressing health issues. His work continues to inspire advancements in medical science.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile